AZN · AstraZeneca PLC

AstraZeneca's Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate, 320/36/9.6μg) received US FDA approval on 28 April 2026 for asthma maintenance in patients aged 12 and older, expanding from its 2020 COPD approval. This positions Breztri as the first single-inhaler triple therapy combining ICS/LABA with LAMA, addressing unmet needs in asthma where approximately half of 27 million US patients remain uncontrolled on dual therapies, leading to exacerbations and reduced quality of life. The approval rests on positive Phase III KALOS and LOGOS trials (results published in The Lancet Respiratory Medicine, February 2026), which enrolled ~4,300 patients and demonstrated statistically significant improvements in primary endpoints—FEV1 AUC 0-3h at Week 24 and trough FEV1—versus dual comparators like Symbicort and PT009, plus rapid onset within five minutes. No new safety signals emerged. For investors, this extends Breztri's strong COPD traction (fastest-growing triple therapy, 6.8M global prescriptions in 2025) into the large asthma market, with filings pending in key regions like EU, Japan, and China, potentially driving Respiratory & Immunology growth.